Clinical trials: Neoplasm, Experimental
Prostate Cancer
A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer
The primary purpose of this study is to determine whether LY2181308 in combination with docetaxel is safe and effective treatment for hormone refractory prostate cancer patients.
- Trial name
- NCT00642018
- Testing
- docetaxel, LY2181308 sodium, Prednisone
- Where
- 17 sites in United States, Germany and 2 more
- Volunteers
- 154 people
- Sponsor
- Eli Lilly and Company
Advanced Melanoma
Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma
This study is to investigate safety and feasibility of a combination therapy of a tumor infiltrating lymphocytes (TIL) transfer with anti-programmed cell death protein (PD)-1 therapy in patients with metastatic melanoma that…
- Trial name
- BaseTIL (NCT04165967)
- Testing
- Combination of TIL Transfer with anti-PD-1 Therapy and low dose IL-2
- Where
- Switzerland
- Volunteers
- 9 people
- Sponsor
- University Hospital, Basel, Switzerland
Hematologic Malignancies
Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation
The purpose of this research study is to determine if an experimental agent, LLME can decrease the incidence and severity of Graft-Versus-Host-Disease (GVHD) following blood (hematopoietic) stem cell transplantation
- Trial name
- NCT00429416
- Testing
- L-leucyl-L-leucine Methyl Ester (LLME), Fludarabine, Cytarabine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Melanoma
An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma
The purpose of this study is to determine whether an investigational immunotherapy Nivolumab, when combined with Ipilimumab, is more effective than Nivolumab by itself, in delaying the return of cancer in patients who have had a…
- Trial name
- CheckMate 915 (NCT03068455)
- Testing
- nivolumab, ipilimumab
- Where
- 124 sites in United States, Australia and 17 more
- Volunteers
- 1,844 people
- Sponsor
- Bristol-Myers Squibb
Gastric Cancer, Gastric Adenocarcinoma
Safety and Efficacy Study With Catumaxomab in Patients After Curative Resection of a Gastric Adenocarcinoma
Investigation of the outcome of an adjuvant treatment with catumaxomab as compared to surgery alone in patients after curative resection of a gastric adenocarcinoma in order to gain more detailed information primary on safety…
- Trial name
- NCT00352833
- Testing
- catumaxomab
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Neovii Biotech
Colorectal Neoplasms
Person-Centred Information and Communication for Patients Undergoing Colo-Rectal Surgery - the PINCORE Project
An overarching aim is to create prerequisites for person-centred information and communication. The specific aim is to evaluate if an intervention with a written information and communication support tool and person-centred…
- Trial name
- PINCORE (NCT03587818)
- Testing
- person-centred communication
- Volunteers
- 488 people
- Sponsor
- Göteborg University
Lung Cancer
An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers
A study to evaluate the safety of Nivolumab given in combination with Ipilimumab in patients with advanced cancers. The initial group will enroll patients with newly diagnosed Stage 4 or non-small cell lung cancer that has come…
- Trial name
- NCT02869789
- Testing
- Nivolumab in combination with Ipilimumab
- Where
- 136 sites in United States, Argentina and 19 more
- Volunteers
- 1,041 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer Screening
Evaluating Interventions for Breast Cancer Screening in Ghana
This study aims to implement two interventions to determine the most effective one that can improve Ghanaian women's decision to get their breasts examined by a healthcare professional.
- Trial name
- NCT07745517
- Testing
- Community Health Nurse-Led Breast Cancer Screening Education, Text Messaging Breast Cancer Screening Educational Intervention, Control Arm - standard of care
- Where
- Ghana
- Volunteers
- 828 people
- Sponsor
- University of Huddersfield
Wound Heal
Safety of Microporous Annealed Particle (MAP) Wound Matrix in Patients With Clean Surgical Wounds.
A randomized, open-label, investigational safety evaluation of the Microporous Annealed Particle (MAP) Wound Matrix (TT101) device as a volumetric biomaterial scaffold applied to clean wounds after skin cancer surgery with Mohs…
- Trial name
- MOSAIC (NCT06600152)
- Testing
- MAP Wound Matrix, DuoDerm
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Tempo Therapeutics
Carcinoma of Urinary Tract, Urethral Carcinoma
Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
This multicenter trial will enroll participants with metastatic transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis who have had disease progression on first-line platinum-based chemotherapy regimens.
- Conditions
- Carcinoma of Urinary Tract, Urethral Carcinoma, Carcinoma of Ureter, Carcinoma of Renal Pelvis
- Trial name
- NCT01282463
- Testing
- Docetaxel, Ramucirumab DP, Icrucumab
- Where
- 32 sites in United States, Canada
- Volunteers
- 148 people
- Sponsor
- Eli Lilly and Company
Neoplasms
Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor
To determine the best dose of this investigational agent AG-013736 in combination with various standard of care treatments for advanced solid tumors.
- Trial name
- NCT00454649
- Testing
- Axitinib + Paclitaxel + Carboplatin (Cohort 1), Axitinib + Paclitaxel + Carboplatin (Cohort 2), Axitinib + Paclitaxel + Carboplatin (Cohort 3)
- Where
- 13 sites in United States, Poland and 1 more
- Volunteers
- 102 people
- Sponsor
- Pfizer
Symptom Management, Breast Care Nurse
Nurse-Led Mobile App Effect on Symptom Management for Breast Cancer Patients After Surgery
Background: The use of the Nurse-Led Mobile App (NL-Mapp) is a current and important option for educating patients about the symptoms that may arise from breast cancer surgery.
- Conditions
- Symptom Management, Breast Care Nurse, Mobile App, Mobile Health
- Trial name
- NCT06505538
- Testing
- NL-Mapp
- Where
- Turkey (Türkiye)
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Gümüşhane Universıty
Acute Myeloid Leukemia
Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
This phase II MyeloMATCH treatment trial compares the combination of azacitidine, venetoclax and quizartinib to the standard treatment of cytarabine, daunorubicin and quizartinib for the treatment of patients with FLT3-ITD mutant…
- Trial name
- NCT07862517
- Testing
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration
- Volunteers
- 122 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor Cancers
A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers
Primary Objective: To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of SAR245408 administered in combination with SAR256212 in adult patients with locally advanced or metastatic solid tumors.
- Trial name
- NCT01436565
- Testing
- MM-121 (SAR256212), SAR245408
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Sanofi
Carcinoma, Non-Small-Cell Lung
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
This study is referred to as the "umbrella master protocol" for pembrolizumab (MK-3475) in the treatment of non-small cell lung cancer (NSCLC).
- Trial name
- NCT04165798
- Testing
- Tumor Imaging, Tumor Tissue Collection, Blood Sample Collection
- Where
- 48 sites in United States, Canada and 8 more
- Volunteers
- 1,065 people
- Sponsor
- Merck Sharp & Dohme LLC
Adenoma
The MORDIS Study Clinical Investigational Plan
To demonstrate the use of WavSTAT4 system during colonoscopy in identifying diminutive colorectal lesions (e.g. hyperplastic polyps) that can be resected and discarded (or even left in-situ) without adverse clinical impact.
- Trial name
- MORDIS (NCT01980134)
- Where
- 6 sites in Czechia, Denmark and 3 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- SpectraScience
Locally Advanced or Metastatic Solid Tumors
MPDL3280A-treatment-IST-UMCG
To be able to evaluate the investigational imaging - 89Zr-MPDL3280A-PET, 89Zr-CD8 imaging and 18F-FB-IL2-PET - as complementary tools for selection of patients to be treated with MPDL3280A, within this treatment trial the…
- Trial name
- NCT02478099
- Testing
- MPDL3280A
- Where
- Netherlands
- Volunteers
- 81 people
- Sponsor
- University Medical Center Groningen
Malignant Tumor
Impact of Family-Centered Empowerment on Caregivers of Children With Cancer: A Quasi-Experimental Study Protocol
The purpose of this trial is to understand the impact of a family empowerment-based intervention program on family caregivers' readiness to care and ability to care.
- Trial name
- NCT06810388
- Testing
- Health education intervention program based on a family-centered empowerment model, Implementation of routine care measures
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Xiaowan Li
Xerostomia, Head and Neck Cancer
Salivary Gland Autotransplantation for Treatment of XRT Induced Xerostomia
Xerostomia, or dry mouth, is a common side effect of head neck radiation. Current treatment options for radiation-induced xerostomia are generally supportive in nature.
- Trial name
- NCT04007081
- Testing
- Bone Marrow Aspiration, Ultrasound Imaging of Salivary Glands, Salivary Assay
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Wisconsin, Madison
Liver Neoplasms
Transarterial Chemoembolization Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
Rationale: This study will compare head to head in patients with hepatocellular carcinoma (HCC) ineligible for surgery or radiofrequency ablation, the standard treatment arm, transarterial chemoembolization with drug-eluting…
- Trial name
- TRENDY (NCT02470533)
- Testing
- Radiation therapy, chemoembolization
- Where
- 11 sites in Belgium, France and 1 more
- Volunteers
- 100 people
- Sponsor
- Erasmus Medical Center